Friday, July 10, 2026

biotech · Dystrophic Epidermolysis Bullosa · Autosomal Recessive Ichthyosis · KRYS

Krystal Biotech Netherlands

Krystal Biotech Netherlands is a biotech organization headquartered in Pittsburgh, USA. It trades on NYSE under ticker KRYS. Primary therapeutic focus areas include Dystrophic Epidermolysis Bullosa, Autosomal Recessive I

2100 Wharton Street, Suite 701, Pittsburgh, PA 15203, US HQ
2016 Founded
306 Employees
Public company Type
KRYS · NYSE Ticker
Company details
Status
Public
HQ
2100 Wharton Street, Suite 701, Pittsburgh, PA 15203, US
Founded
2016
Employees
306
Programs
14
Drugs
7
Patents
14
Clinical program

LY2456302

Phase 1 · small molecule · Anxiety Disorders

LY2456302 for Anxiety Disorders is a Phase 1 program (small_molecule) at Krystal Biotech Netherlands B.V. with 1 ClinicalTrials.gov record(s).

← All Krystal Biotech Netherlands B.V. projects Phase 1 small molecule terminated

Internal code Pro00052483

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Krystal Biotech Netherlands B.V.
Phase
Phase 1
Modality
small_molecule
Indication
Anxiety Disorders
Status
terminated
Trials
1

Clinical trials